Lantheus (LNTH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Sep, 2026Executive summary
Special meeting of stockholders scheduled for October 14, 2026, to vote on the proposed acquisition by Curium US Holdings LLC under the Merger Agreement dated August 3, 2026.
Board of Directors unanimously recommends voting in favor of the Merger Agreement and related proposals.
Stockholders are urged to vote promptly, as not voting will have the same effect as voting against the merger.
Voting matters and shareholder proposals
Main proposal is the approval of the Merger Agreement with Curium US Holdings LLC and related proposals.
Board recommends a FOR vote on all proposals related to the merger.
Voting can be done via Internet, telephone, mail, or email link.
Board of directors and corporate governance
Board of Directors is actively soliciting proxies and providing guidance to stockholders regarding the merger.
Executive Chairperson and Interim CEO, Mary Anne Heino, is leading communications to stockholders.
Latest events from Lantheus
- Shareholders to vote on $102.50 cash plus CVR merger; board unanimously recommends approval.LNTH
Proxy filing - Shareholders to vote on merger creating a global radiopharmaceutical leader, closing in 2027.LNTH
Proxy filing - Q2 2026 revenue up 2.7%, adjusted EPS $1.55, and merger with Curium valued up to $8B announced.LNTH
Q2 2026 - Curium and Lantheus announce a merger to create a global leader in diagnostics and therapeutics.LNTH
Proxy filing - Shareholders to receive $102.50 per share plus up to $12.00 in CVRs, pending milestone achievements.LNTH
Proxy filing - Definitive merger agreement with Curium offers up to $114.50 per share, closing expected in H1 2027.LNTH
Proxy filing - Curium to acquire Lantheus for up to $114.50/share, creating a global radiopharmaceutical leader.LNTH
Proxy filing - Q3 2025 revenue up 1.4% to $384M; adjusted EPS $1.27; major acquisitions and leadership changes.LNTH
Q3 2025 - PYLARIFY drives growth as market leader, with new diagnostics and therapeutics set to expand the portfolio.LNTH
The 44th Annual William Blair Growth Stock Conference